PriceTargets.com logo

Alliance Pharma - APH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 60
  • Forecasted Upside: 31.29%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 45.70 As of 12/23/2024 12:51 PM ET
▼ -0.275 (-0.60%)

This chart shows the closing price for APH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alliance Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APH

Analyst Price Target is GBX 60
▲ +31.29% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Alliance Pharma in the last 3 months. The average price target is GBX 60, with a high forecast of GBX 60 and a low forecast of GBX 60. The average price target represents a 31.29% upside from the last price of GBX 45.70.

This chart shows the closing price for APH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Alliance Pharma. This rating has held steady since September 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/31/2024Royal Bank of CanadaLower TargetOutperformGBX 65 ➝ GBX 60
9/26/2023Peel HuntReiterated RatingHoldGBX 53
5/25/2023Numis SecuritiesReiterated RatingBuyGBX 105
5/25/2023Berenberg BankReiterated RatingBuyGBX 105
3/17/2023Peel HuntInitiated CoverageHoldGBX 65
2/1/2023Numis SecuritiesReiterated RatingBuyGBX 110
1/17/2023Berenberg BankLower TargetBuyGBX 110 ➝ GBX 105
9/20/2022Berenberg BankReiterated RatingBuyGBX 145
8/8/2022Royal Bank of CanadaReiterated RatingOutperformGBX 130
7/14/2022Berenberg BankReiterated RatingBuyGBX 145
6/15/2022Berenberg BankReiterated RatingBuyGBX 145
3/24/2022Royal Bank of CanadaReiterated RatingOutperformGBX 130
1/28/2022Royal Bank of CanadaBoost TargetOutperformGBX 106 ➝ GBX 121
6/29/2021Numis SecuritiesReiterated RatingBuyGBX 120
(Data available from 12/23/2019 forward)

News Sentiment Rating

1.21 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Alliance Pharma logo
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.
Read More

Today's Range

Now: GBX 45.70
Low: 45.50
High: 46.50

50 Day Range

MA: GBX 45.97
Low: 42.90
High: 49

52 Week Range

Now: GBX 45.70
Low: 24.55
High: 50.26

Volume

218,462 shs

Average Volume

1,473,126 shs

Market Capitalization

£247.04 million

P/E Ratio

N/A

Dividend Yield

3.75%

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Alliance Pharma?

The following Wall Street sell-side analysts have issued reports on Alliance Pharma in the last twelve months: Royal Bank of Canada.
View the latest analyst ratings for APH.

What is the current price target for Alliance Pharma?

0 Wall Street analysts have set twelve-month price targets for Alliance Pharma in the last year. Their average twelve-month price target is GBX 60, suggesting a possible upside of 31.3%. Royal Bank of Canada has the highest price target set, predicting APH will reach GBX 60 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of GBX 60 for Alliance Pharma in the next year.
View the latest price targets for APH.

What is the current consensus analyst rating for Alliance Pharma?

Alliance Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APH will outperform the market and that investors should add to their positions of Alliance Pharma.
View the latest ratings for APH.

What other companies compete with Alliance Pharma?

Other companies that are similar to Alliance Pharma include Spire Healthcare Group, The Restaurant Group, Empiric Student Property, International Personal Finance and Sigma Capital Group. Learn More about companies similar to Alliance Pharma.

How do I contact Alliance Pharma's investor relations team?

Alliance Pharma's physical mailing address is Avonbridge House, Bath Road, CHIPPENHAM, SN15 2BB, United Kingdom. The company's listed phone number is +44-1249-466966. The official website for Alliance Pharma is www.alliancepharma.co.uk. Learn More about contacing Alliance Pharma investor relations.